12月4日 - ** Vanda Pharmaceuticals VNDA.O股价盘后上涨近7%，至5.55美元左右
** 美国食品和药物管理局解除了对 (link) 公司治疗晕动病的替替匹坦的部分临床试验禁令
** 这一决定允许万达公司延长对tradipitant的临床研究。
** 股票今年累计上涨 8.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.